Purple Biotech receives intention to grant a European patent covering NT219

Purple Biotech (PPBT) announced that the Examining Division of the European Patent Office has issued an intention to grant a European Patent for Application No. 20168234.1, titled ‘Combinations of IRS/STAT3 Dual Modulators and Anti-Cancer Agents for Treating Cancer’. This application, if granted, is expected to provide broad protection for NT219 combinations with leading immunotherapies, such as anti-PD-1, PD-L1, CTLA-4, and CD20 antibodies, which are designed to enhance responsiveness in resistant cancers. It further covers combinations of NT219 with MEK inhibitors that may expand treatment sensitivity for resistant tumors. Finally, the application includes claims for combinations of NT219 with selected chemotherapies or targeted agents to address cancers that develop resistance driven by KRAS amplification or mutation. The patent term, excluding extensions, runs through 2036.